Search the web
Welcome, Guest
[Sign Out, My Account]
Morningstar_Inc.

Monday, September 15 2014 5:27am ET - U.S. Markets open in 4 hours and 3 minutes.
Industry Center - Biotechnology
Industry Center > Biotechnology
More On This Industry
Summary
·News
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
Top Industries
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Diversified Utilities
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
·Tobacco Products, Other
Complete Industry List...
Morningstar Inc.
In-depth Company Dossier Reports on over 7,500 publicly traded U.S. companies. Click here for your free report.
  
Industry Market Summary
Biotechnology
Composite Value: 1576.6
Today's Change: -0.78%
S&P 500: -0.60%
chart for
[Biotechnology (^YHOh788)]
Biotechnology News
Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure
Sun 9:00 pm ET (PR Newswire)
THOUSAND OAKS, Calif., Sept. 14, 2014 /PRNewswire/ -- Amgen (AMGN) today announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Las Vegas. A post-hoc analysis from the SHIFT study confirmed low systolic blood pressure (SBP) is associated with poor outcomes in chronic HF, and that ivabradine reduced the primary composite endpoint of cardiovascular death or hospitalization for worsening HF in this subgroup with low baseline SBP. Ivabradine is an oral drug that inhibits the If current ("funny" current) in the sinoatrial node, the body's cardiac pacemaker.2 It works to slow the heart rate without negative effects on myocardial contractility or ventricular repolarization.2 "Despite standard of care, chronic heart failure remains a disabling condition with a poor prognosis for patients at risk for hospitalization," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.
Improved Survival Observed in Pediatric Patients with Severe Hypophosphatasia (HPP) Who Were Treated with Investigational Asfotase Alfa for Up to Five Years - (Business Wire)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Enzymotec Ltd. to Contact Brower Piven Before the November 4, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- ENZY - (GlobeNewswire)
More News on Biotechnology: Latest News,
Industry Top Performers
Intraday Price Performance% ChangeMarket Cap
BIOPHARMX CORPORATIO [BPMX] +22.22% -$1000.0 K
Aldeyra Therapeutics, Inc. [ALDX] +21.20% $31.4 M
NOVACYT [ALNOV.PA] +21.00% $0
CLINUVEL FPO [CUV.AX] +16.53% $0
ADOCIA [ADOC.PA] +15.38% $0
More Top Intraday Price Performers...
Market Capitalization% ChangeMarket Cap
SHIRE [SHP.L] -0.28% $3105.0 B
GILEAD SCIENCES [GILD.MX] -2.91% $2071.0 B
SUN PHARMA- DEPO SETT [SUNPHARMA.NS] -0.68% $1669.6 B
AMGEN [AMGN.MX] +1.22% $1390.1 B
Gilead Sciences, Inc. [GILD] -2.57% $156.7 B
More Top Companies by Market Cap...
More Top Performers: by Valuation, by Growth, by Financial Strength
Industry Calendar
Upcoming Events
Date Co Event
09/15/14 ALMED.PA Medicrea International SA Q2 2014 Earnings Release
09/16/14 SLN.L Half Year 2014 Silence Therapeutics PLC Earnings Release
09/17/14 IPH.PA Half Year 2014 Innate Pharma SA Earnings Release
More Upcoming Events...
Recent Events
Date Co Event
09/12/14 EPZM Epizyme, Inc. coverage initiated by Mizuho
09/12/14 NLNK NewLink Genetics Corporation coverage initiated by Mizuho
09/11/14 PSTI Pluristem Therapeutics, Inc. upside earnings surprise (+40.00%)
More Recent Events...
Sponsor Results
Breakthrough For Diabetes
Learn this natural method to help control blood sugar
www.newresearchintohealth.com
Dr0zs Wrinkle System - $5
Read this special report (by Dr0zs) on 1 new Wrinkle Cream that Works!
antiagingworld.org/AntiAgingCreams
Market Research Reports
Industry, Market & Company Research For Planning & Business Executives
www.vpgmarketresearch.com
(What's This?)
  
Locate Industry by Company
Enter Symbol:
Industry Statistics
Market Capitalization:9,847B
Price / Earnings:NM
Price / Book:30.5
Net Profit Margin (mrq):6.7%
Price To Free Cash Flow (mrq):-115.5
Return on Equity:5.1%
Total Debt / Equity:49.5
Dividend Yield:1.8%
View Industry Browser
Community Spotlight
Most Active Boards
Board Popularity
CTRX
PGLAF
NRPH
Unusually Active Boards
Board Variance
CTRX
NRPH
PDLI

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Biotechnology Headlines
More Finance RSS Feeds


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2014 Morningstar, Inc. All Rights Reserved. Company information © 2014 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?